Which hedge funds own TRVI? TREVI THERAPEUTICS INC, Q2 2026 13F holders
47 tracked hedge funds disclosed a position in TRVI (TREVI THERAPEUTICS INC) in their Q2 2026 13F filings, worth $884.2m in total. The largest holder by portfolio weight is Artia Global Partners LP at 7.8% of its book. 14 opened a new position this quarter: Saturn V Capital Management LP, First Light Asset Management, LLC, Rock Springs Capital Management LP, Integral Health Asset Management, LLC. 10 exited: Propel Bio Management, LLC, GMT Capital Corp, Diadema Partners LP.
- 47
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 14
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 10
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $84.6m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $31.0m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $884m
- Combined value Sum of the holders' reported positions in the security.
- 3.8%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Propel Bio Management, LLC | 1.7% | $2.6m |
| GMT Capital Corp | 0.2% | $3.8m |
| Diadema Partners LP | 0.1% | $258k |
| Citadel Advisors LLC | 0.01% | $14.3m |
| ExodusPoint Capital Management, LP | 0.01% | $953k |
| Millennium Management LLC | 0.01% | $6.8m |
| Squarepoint Ops LLC | 0.0% | $1.2m |
| Hudson Bay Capital Management LP | 0.0% | $140k |
| Two Sigma Investments, LP | 0.0% | $458k |
| AQR Capital Management LLC | 0.0% | $336k |
Ownership over time
Who discovered TRVI first? Beta
The run: Q2 2025 → Q2 2026, +241%
| MPM Bioimpact LLC high conviction | Q4 2024 | 3.2% | +6.2 pts |
| Frazier Life Sciences Management, L.P. | Q4 2024 | 2.2% | +5.5 pts |
| Artia Global Partners LP high conviction | Q2 2025 | 1.8% | +5.3 pts |
| Octagon Capital Advisors LP | Q1 2025 | 4.4% | +4.8 pts |
| Affinity Asset Advisors, LLC | Q1 2025 | 2.0% | +2.8 pts |
| Logos Global Management LP | Q3 2024 | 0.6% | +2.4 pts |
| Sphera Funds Management Ltd. | Q2 2025 | 1.1% | +1.9 pts |
| Rubric Capital Management LP | Q3 2025 | 0.8% | +1.6 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.